|
|||||
|
|
Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer |
|
| Authors: | Vincent A. DiPippo Holly M. Nguyen Lisha G. Brown William C. Olson Robert L. Vessella Eva Corey |
| Affiliation: | 1. Progenics Pharmaceuticals, Inc., Tarrytown, New York;2. Department of Urology, University of Washington, Seattle, Washington |
| Abstract: | |
| Keywords: | PSMA ADC prostate cancer patient‐derived xenografts |